Placebo Olanzapine

DRUG3 trials

Sponsors

Organon and Co, Forest Laboratories, Central Institute of Mental Health, Mannheim

Conditions

Schizophrenia

Phase 2

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

TerminatedNCT02088060

Central Institute of Mental Health, MannheimSchizophrenia

Start: 2015-12-08End: 2024-09-16Target: 150Updated: 2024-12-27

Phase 3

A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

CompletedNCT01617187

Organon and CoSchizophrenia

Start: 2012-12-04End: 2014-09-09Updated: 2024-06-18

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

CompletedNCT01617200

Forest LaboratoriesSchizophrenia

Start: 2012-12-31End: 2015-03-31Updated: 2015-05-27